Evicenter
Keytruda (pembrolizumab) in High-risk early-stage triple-negative breast cancer
Manufacturer
Merck Sharp & Dohme LLC
Prescribing information
Keytruda (opens in a new tab)
Questions
28
Last updated

All questions

Dosing and administration: Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer

2 questions · 3 sources

Dosing

What is the KEYTRUDA dose for high-risk early-stage TNBC?

Can the KEYTRUDA dose be reduced for side effects?